Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2010 Jun 1;28(19):3167–3175. doi: 10.1200/JCO.2009.26.7609

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2010 by American Society of Clinical Oncology

PMC Copyright notice

Fig 3. — Effects of a single dose of anti–programmed death-1 monoclonal antibody (MDX-1106; 10 mg/kg) on circulating lymphocyte numbers. (A) Twenty-four hours postdose, a decline in total lymphocyte as well as CD3, CD4, and CD8 numbers was observed (two-sided P = .004, .002, < .001, and .01 respectively; Wilcoxon signed rank test). These parameters followed similar trends, rebounding from days 2 through 29 (two-sided P < .001; two-sided P = .01 for CD8), and declining again from days 29 through 85 (two-sided P < .001; mixed model test for trend with knots [changes in slopes] and repeated measures). Means ± standard error of mean are shown; numbers of patients studied at each time point are indicated in parentheses. (B) Paired analysis of total lymphocyte numbers in 16 patients, comparing immediate pretreatment samples (day 1) with 24-hour post-treatment samples (day 2). A significant decline at day 2 was observed (two-sided P = .004; Wilcoxon signed rank test). Dotted line indicates the lower limit of normal lymphocyte counts.